Polymorphisms of CYP1B1 and COMT in Breast and Endometrial Cancer

Zimarina, T. S.; Kristensen, Vessela N.; Imyanitov, Evgeny N.; Berstein, Lev M.

doi:10.1023/b:mbil.0000032200.95457.69

Cited by 21 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning Arg48Gly polymorphism, 10 studies were eligible (11,321 cases and 13,379 controls) [9,22,23,[28][29][30][31][32][33]; 11 studies were eligible for Ala119Ser (10,715 cases and 11,678 controls) [9,22,23,28,31,[34][35][36][37][38]; 12 cases were eligible regarding Asn453Ser (11,630 cases and 14,053 controls) [22, 29-32, 35, 39-43].…”

Section: Eligible Studiesmentioning

confidence: 99%

Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis

Economopoulos

Sergentanis

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. Abstract Cytochrome P450 1B1 (CYP1B1) is a P450 enzyme implicated in the metabolism of exogenous and endogenous substrates. The metabolism of polycyclic aromatic hydrocarbons and other procarcinogens through CYP1B1 may well lead to their activation. Apart from the extensively studied Val432Leu polymorphism, three single nucleotide polymorphisms in CYP1B1 have been studied concerning their potential implication in terms of breast cancer risk: Arg48Gly, Ala119Ser and Asn453Ser. This meta-analysis aims to examine whether the three aforementioned polymorphisms are associated with breast cancer risk. Eligible articles were identified by a search of MEDLINE bibliographical database for the period up to December 2009. Concerning Arg48Gly polymorphism, 10 studies were eligible (11,321 cases and 13,379 controls); 11 studies were eligible for Ala119Ser (10,715 cases and 11,678 controls); 12 cases were eligible regarding Asn453Ser (11,630 cases and 14,053 controls). Pooled odds ratios (OR) were appropriately derived form fixedeffects or random-effects models. Sensitivity analysis excluding studies whose genotype frequencies in controls significantly deviated from Hardy-Weinberg equilibrium was performed. Concerning Arg48Gly, the pooled ORs (95% CI) were 0.933 (0.808-1.078) for heterozygous and 0.819 (0.610-1.100) for homozygous Gly subjects. Regarding Ala119Ser, the pooled ORs were 0.992 (0.896-1.097) for heterozygous and 0.935 (0.729-1.198) for homozygous Ser subjects. With respect to Asn453Ser, the pooled ORs were 0.961 (0.906-1.019) for heterozygous and 0.984 (0.846-1.144) for homozygous Ser subjects. In conclusion, this meta-analysis suggests that CYP1B1 Arg48Gly, Ala119Ser and Asn453Ser polymorphisms are not associated with breast cancer risk. Studies on Chinese populations are needed, to elucidate race-specific effects on East Asian populations, if any.

show abstract

Section: Eligible Studiesmentioning

confidence: 99%

Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis

Economopoulos

Sergentanis

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…A total of 15 studies with full-text articles examined the association of COMT Val158Met polymorphism with endometrial and ovarian cancer were found (Goodman et al, 2000;Goodman et al, 2001;Garner et al, 2002;McGrath et al, 2004;Zimarina et al, 2004;Doherty et al, 2005;Sellers et al, 2005;Tao et al, 2006;Holt et al, Szyllo et al, 2007;Zhao et al, 2007;Delort et al, 2008;Hirata et al, 2008). As summarized in (Table 1), the eligible studies were selected for this meta-analysis, including 1, 293 cases and 2, 647 controls for ovarian cancer (from eight studies) and 2, 174 cases and 2, 699 controls for endometrial cancer (from seven studies).…”

Section: Eligible Studies and Meta-analysis Databasesmentioning

confidence: 99%

“…It has been hypothesized that this COMT polymorphism (rs4680) may modulate risk of hormonally responsive cancers because of a decreased ability of COMT to methylate and thereby inactivate catechol estrogens, as well as through decreased production of the intermediate products of catechol estrogen metabolism (Lajin et al, 2013). To data, several epidemiologic studies have investigated the relationship between the COMT polymorphism and predisposition to endometrial and ovarian cancer (Goodman et al, 2000;Goodman et al, 2001;Garner et al, 2002;McGrath et al, 2004;Zimarina et al, 2004;Doherty et al, 2005;Sellers et al, 2005;Tao et al, 2006;Holt et al, 2007;Szyllo et al, 2007;Wang et al, 2007;Zhao et al, 2007;Delort et al, 2008;Hirata et al, 2008;Jakubowska et al, 2010). Although it is an appealing hypothesis that genes affecting the production or metabolism of estrogen may affect the risk of hormonally related cancers, the evidence from the literature is inconsistent.…”

Section: Introductionmentioning

confidence: 99%

Lack of Associations of the COMT Val158Met Polymorphism with Risk of Endometrial and Ovarian Cancer: a Pooled Analysis of Case-control Studies

Liu

Luo²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (15), 6181-6186 IntroductionOvarian cancer is associated with the highest mortality rate among gynaecological malignancies (Hennessy et al., 2009). There are over 205, 000 new cases and 125, 000 deaths annually from ovarian cancer (Jemal et al., 2011). Endometrial cancer is the fourth most common cancer among women and the most common gynecological cancer in the USA (Jemal et al., 2009). Multiple lines of evidence support a central role of hormones in the etiology of endometrial and ovarian cancers (Lundin et al., 2012). Polymorphisms within genes responsible for estrogen catabolism could alter cellular levels of genotoxic 4-hydroxylated catechol estrogens and antiangiogenic 2-methoxyestradiol, thus influencing risk of developing endometrial and ovarian cancers.Catechol-O-methyltransferase (COMT) catalyzes catechol estrogens to form methyl conjugates, a process that detoxifies the catechol estrogens and prevent them from forming depurinating adducts. In addition, the intermediate products of catechol estrogen metabolism,

show abstract

“…Adopting the same search strategy and end-of-search date as Yao et al [1], we have located three relevant case-control studies in MEDLINE with a total number of 685 breast cancer cases and 931 controls, which have not been included in the meta-analysis [2][3][4]. Of note, all three casecontrol studies were performed on Caucasian populations.…”

Section: Dear Editormentioning

confidence: 99%

Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis

Economopoulos

Sergentanis

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Polymorphisms of CYP1B1 and COMT in Breast and Endometrial Cancer

Cited by 21 publications

References 23 publications

Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis

Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis

Lack of Associations of the COMT Val158Met Polymorphism with Risk of Endometrial and Ovarian Cancer: a Pooled Analysis of Case-control Studies

Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis

Contact Info

Product

Resources

About